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Available online 26 May 2016We aimed to investigate long-term outcomes in psychoticmajor depression patients compared to schizophrenia
and bipolar/manic psychosis patients, in an incidence sample, while accounting for diagnostic change.
Based onAetiology andEthnicity in Schizophrenia andOther Psychoses (ÆSOP andÆSOP-10), a first episode psy-
chosis cohort was followed-up 10 years after first presentation. The Schedules for Clinical Assessment in Neuro-
psychiatry, WHO Life Chart and Global Assessment of Functioning were used to assess clinical, social and service
use outcomes.
Seventy-two PMD patients, 218 schizophrenia patients and 70 psychotic bipolar disorder/mania patients were
identified at baseline. Differences in outcome between PMD and bipolar patients based on baseline and lifetime
diagnosiswereminimal. Differences in clinical, social and service use outcomes between PMD and schizophrenia
weremore substantial with PMDpatients showing better outcomes onmost variables. However, therewas some
weak evidence (albeit not quite statistically significant at p b 0.05) based on lifetime diagnoses that PMDpatients
weremore likely to attempt suicide (OR 2.31, CI 0.98–5.42, p0.055) and self-harm (OR 2.34, CI 0.97–5.68, p0.060).
PMD patients have better social and service use outcomes compared to people with schizophrenia, but may be
more likely to attempt suicide or self-harm. This unique profile is important for clinicians to consider in any
risk assessment.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Prognosis1. Introduction
Major depression with psychotic features, also known as Psychotic
Major Depression (PMD), is defined by ICD–10 (WHO, 1993) as a de-
pressive disorder with the addition of delusions, hallucinations or de-
pressive stupor. A systematic review and meta-analysis by Kirkbride
et al. (2012) reported a pooled incidence for PMD in England of 5.3
(95% CI 3.7–7.6) per 100,000 person years. This was compared with
3.7 per 100,000 person years (95% CI 3–4.5) for bipolar with psychoticInstitute of Psychiatry at King's
6 De Crespigny Park, Denmark
.
. This is an open access article undersymptoms and 15.2 per 100,000 person years (95% CI 11.9–19.5) for
schizophrenia. These results suggest that PMD is less common than
schizophrenia, but more common than bipolar disorder. Despite these
incidence rates, PMD is a largely under-researched disorder (Crebbin
et al., 2008).
Many studies have investigated the long-term course of illness and
outcomes in psychosis (Ciompi, 1980; Harrison et al., 2001; Hill et al.,
2012; Takei et al., 1998). However, studies have less often included out-
comes on PMD patients (Ciccone and Racy, 1975; Schimmelmann et al.,
2005; DelBello et al., 2003; Bromet et al., 1996) and importantly, few
have compared outcomes in people with PMD to outcomes in other
major psychotic diagnostic groups such as schizophrenia and bipolar
patients. Further, many studies which include outcomes for PMD are
based on prevalence samples or samples of only inpatients, both of
which are biased towards those with longer duration and more severethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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picture of long-term prognosis.
The four studies which have to date examined outcomes in PMD
patients in incidence samples (Crebbin et al., 2008; Amin et al., 1999;
Baldwin et al., 2005;Whitty et al., 2005)were conducted over a relative-
ly short period of time (6 months–4 years); therefore, knowledge of
longer-term outcomes is limited. While, three of these studies exam-
ined diagnostic stability only (Amin et al., 1999; Baldwin et al., 2005;
Whitty et al., 2005). Crebbin et al. (2008) also reported some clinical
and service use outcomes. They found that there was a similar percent-
age of deaths in the year after first presentation in the people with PMD
(9.5%, n10/105) and schizophrenia (9.6%; n7/73). They also reported no
difference in number of admissions or admission days between those
with PMD and those with schizophrenia, but more use of compulsory
admissions in schizophrenia patients. Although the authors state that
diagnosis was stable in PMD at 87%, this is contrary to findings in
other studies (65% (Amin et al., 1999), 73% (Whitty et al., 2005), b50%
(Heslin et al., 2015)). Based on these studies, accounting for diagnostic
stability is important for outcome research in PMDpatients who change
diagnosis may have different outcomes compared to those who start
with that diagnosis and retain it over time.
1.1. Aims of the study
Given the paucity of information on long-term outcomes for PMD
patients in less biased samples, we aimed to examine long term
(10 year) outcomes in people with PMD, while improving on the meth-
odological limitations of previous research by studying an incidence
sample (the ÆSOP study), and accounting for diagnostic change. Out-
comes in people with PMDwere compared to outcomes for schizophre-
nia and bipolar/manic psychosis patients. Specifically, we chose to
investigate the following aspects of outcome in PMD patients: clinical
outcomes (symptoms, course of illness, suicide attempts and self-
harm); social outcomes (disability, employment, relationship status,
close confidants and time in prison); and service use outcomes (days
hospitalised and compulsory admissions).
2. Methods
This paper is based on theÆSOP-10 study which is fully described in
Morgan et al. (2014) In brief, ÆSOP-10 is a 10 year follow-up of a cohort
of peoplewith a first episode of psychosis. The original cohort was iden-
tified from all inpatient and outpatient mental health services in two
well defined catchment areas in the UK (Kirkbride et al., 2006). At base-
line, detailed information was collected to enable re-contact for all pa-
tients. We aimed to trace, re-contact and re-interview all patients at
approximately 10 years. Patients were contacted via current mental
health services, if in contact with services, by inviting them to partici-
pate through their clinical teams. For those not in contact with services,
letters were sent to their last known address inviting them to partici-
pate. Non-responders were sent a further letter two weeks later with
a maximum of three visits to the address if needed to make initial con-
tact. For those believed to havemoved address, we sought tomake con-
tact and invite them to participate through their GP if known.
2.1. Measures
At baseline, data on demographics (age, gender, ethnicity, centre,
place of birth) were collected using the Medical Research Council
Socio-demographic Schedule (Mallett, 1997). The Schedules for Clinical
Assessment in Neuropsychiatry (SCAN version 2 (WHO, 1994)) was
used to elicit symptom-related data at the time of presentation. Symp-
tom data plus all available clinical information (excluding diagnosis)
was used to assign ICD-10 (WHO, 1993) psychotic diagnoses within
consensus meetings involving the research team. These meetings in-
volved at least one senior psychiatrist. Diagnosis was made as soon aspossible after first contact (generally within a few weeks). Diagnoses
were made blind to ethnicity and diagnosis from the clinical notes.
A range of measureswere used to collect data at follow-up. Relevant
to this paper are the SCAN, the WHO Life Chart and the Global Assess-
ment of Functioning (GAF). The SCAN was repeated where interview
with patients were possible, and completed in relation to the preceding
month. An extended version (detailed in Morgan et al. (2014)) of the
WHO Life Chart (Harrison et al., 2001; Sartorius et al., 1996; Burns
et al., 1999) was completed for each patient using where possible, clin-
ical interviews with patients and information from treating clinicians
plus clinical notes, to map course of illness and symptom history. The
Life Chart collates information on course of illness and three key areas
of outcome: clinical; social; and service use. Items from the Life Chart
relevant to this paper were: course of illness (episodic, continuous or
neither); occurrence of suicide attempts and self-harm; relationship
status, employment status, presence of a close confidant and whether
the person spent any follow-up time in prison; and number of days as
an inpatient and ever compulsorily admitted. Suicide attemptswere de-
fined as a deliberate act of self-harm with the intention of ending one's
life. If there was any doubt about the intention, then it was rated as self-
harm. Self-harmwas defined as intentional injury to one's body. If there
was any doubt about whether something was deliberate, it was not
counted. The split GAF was used to characterise overall symptomatolo-
gy and function in the month prior to follow-up (Harrison et al., 2001,
adapted from Endicott et al., 1976) based on presentation at follow-
up: the GAF symptom scale; and the GAF disability scale. Higher GAF
scores indicate fewer symptoms or a better level of functioning. Infor-
mation from the SCAN at follow-up and Life Chart were used to deter-
mine lifetime diagnosis using the consensus approach as at baseline,
and blind to ethnicity and baseline diagnosis.
2.2. Ethics
Full ethical approval for all aspects of the follow-up was provided by
the local research ethics committees in South East London and Notting-
ham. All researchers had substantive or honorary contracts with either
the South London and Maudsley National Health Service (NHS) Founda-
tion Trust or the Nottingham Healthcare NHS Trust, the primary partici-
pating service providers.
2.3. Analyses
All data were analysed using STATA (version 11; StataCorp, 2009).
Data were described using means and standard deviations, medians
and interquartile ranges or frequencies and percentages as appropriate.
Outcomes for PMD patients were compared with outcomes for bipolar
disorder and schizophrenia patients. Categorical outcomeswere analysed
using logistic regression. Continuous outcomes were analysed using
bootstrap regression (1000 replications) to account for the skewed
nature of the data (Kielhorn and Graf vonSchulenberg, 2000). Bootstrap
regression analyses produce the same coefficients are interpreted in the
same way as linear regressions but produce more robust confidence
intervals.
3. Results
A total of 557 first episode patients were identified at baseline. Data
presented here are based on the incidence sample (n, 505) collected
over the first 2 years (excluding: non-incidence patients collected for
the brain imaging component of the study; patients oversampled in
the 3rd year in order to increase the numbers for the ethnicity compo-
nent of the study; and patients excluded post baseline). Data presented
here are for the PMD, schizophrenia and bipolar disorder/mania
patients only (n360) (i.e., excluding delusional disorder, schizoaffective
disorder, acute & transient psychoses, drug induced psychoses and
psychoses NOS).
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Of the 360 patients included here, 72 had a baseline diagnosis of
PMD, 218 had a diagnosis of schizophrenia, and 70 had a diagnosis of
bipolar disorder or mania with psychotic symptoms at baseline.
Table 1 describes the demographics of these three groups and the sam-
ple overall. Of the 360 patients of interest, 24 patients had died and 23
patients had moved abroad. Two hundred and sixty eight had some
follow-up data at 8–12 years (54 PMD patients, 161 schizophrenia pa-
tients and 53 bipolar/mania patients). Therefore only 45 patients were
lost to follow-up (12.5%). Differences in the proportion followed up by
diagnostic group were compared, and found not to differ (Chi2 (2df)
0.11, p 0.946).
3.2. Outcomes by baseline diagnosis
Outcomes are described only for the core analytic sample (excluding
thosewhodied,moved abroad orwere lost to follow-up as described by
Morgan et al. (2014). Table 2 describes the outcomes by baseline diag-
nosis for PMD, schizophrenia and bipolar/mania patients. The table
shows that the only differences between PMD patients and bipolar
patients were as follows: episodic course of illness whichwas less likely
in PMD patients (OR 0.16, CI 0.06 to 0.40, p b 0.01); GAF disability score
at follow-up which was lower in PMD patients (indicating worse func-
tioning, coefficient−10.85, CI−18.66 to−3.04, p b 0.01); and having
been compulsorily admitted,whichwas far less likely to happen to PMD
patients (OR 0.22, CI 0.08 to 0.59, p b 0.01).
There were more differences between PMD and schizophrenia
patients. Compared with those with schizophrenia, PMD patients had
a higher GAF symptom score at follow-up (indicating better function-
ing, coefficient 14.25, CI 8.13 to 20.37, p b 0.01); were more likely to
have an episodic course of illness (OR 3.02, CI 1.46 to 6.25, p b 0.01);
had a higher GAF disability score at follow-up (coefficient 11.22, CI
4.78 to 17.65, p b 0.01); were less likely to be employed for less than
25% of the follow-up (OR 0.34, CI 0.16 to 0.70, p b 0.01);weremore like-
ly to be in a relationship over the follow-up (OR 4.14, CI 1.95 to 8.78,
p b 0.01), were less likely to spend time in prison (OR 0.22, CI 0.05 to
0.97, p b 0.05); were less likely to be admitted compulsorily (OR 0.37,
CI 0.18 to 0.76, p b 0.01); and spent fewer inpatient days in hospital (co-
efficient−161.98, CI−272.25 to−51.70, p b 0.01).Table 1
Baseline demographics of full sample and by diagnostic groups.
Age PMD
(n72)
Schizophrenia
(n218)
Bipolar
(n70)
Overall sample
(n360)
Median
(IQR)
Median
(IQR)
Median
(IQR)
Median
(IQR)
32.50
(25–41)
29.00
(22–35)
27.00
(23−33)
29.00
(23–36)
N (%) N (%) N (%) N (%)
Study centre:
London 35 (48.6) 151 (69.3) 44 (62.9) 230 (63.9)
Nottingham 37 (51.4) 67 (30.7) 26 (37.1) 130 (36.1)
Gender:
Male 36 (50.0) 140 (64.2) 33 (47.1) 209 (58.1)
Female 36 (50.0) 78 (35.8) 37 (52.9) 151 (41.9)
Ethnicity:
White British 37 (51.4) 81 (37.2) 27 (38.6) 145 (40.3)
African-Caribbean 8 (11.1) 61 (28.0) 14 (20.0) 30 (8.3)
Black African 7 (9.7) 33 (15.1) 11 (15.7) 83 (23.1)
White Other 4 (5.6) 22 (10.9) 4 (5.7) 51 (14.2)
Asian 7 (9.7) 10 (4.6) 6 (8.6) 23 (6.4)
Other (all) 9 (12.5) 11 (5.1) 8 (11.4) 28 (7.8)
Place of birth:
UK 50 (69.4) 148 (69.8) 53 (76.8) 251 (71.1)
Non-UK 22 (30.6) 64 (30.2) 16 (23.2) 102 (28.9)
IQR = interquartile range.3.3. Outcomes by lifetime diagnosis
Table 3 describes the outcomes by lifetime diagnosis for PMD,
schizophrenia and bipolar/mania patients as well as comparisons
between the PMD group and schizophrenia group, and the PMD and
bipolar group. Data on diagnostic change are presented elsewhere
(Heslin et al., 2015). In brief, of the 403 with baseline and lifetime diag-
nostic data, 15 changed from a baseline diagnosis of PMD to a follow-up
diagnosis of schizophrenia, and seven changed from a baseline diagno-
sis of PMD to a lifetime diagnosis of bipolar disorder. Eight changed from
schizophrenia to PMD, and two changed from bipolar to PMD. In terms
of comparisons between PMD and BP patients, similarly to the baseline
analyses, PMD patients had a lower GAF disability score at follow-up
(indicating worse functioning, coefficient −10.16, CI −18.99 to
−1.33, p b 0.05); andwere less likely to have been compulsorily admit-
ted (OR 0.32, CI 0.12 to 0.84, p b 0.05). GAF symptom score became sig-
nificantly different between the groups with PMD patients having a
lower score (and therefore worse symptoms, coefficient −8.77, CI
−16.86 to−0.69, p b 0.05). PMD patients were still less likely to have
an episodic course of illness but this was not statistically significant
(OR 0.44, CI 0.18 to 1.07, p 0.071).
Comparisons between PMD and schizophrenia patients again re-
vealed a large number of differences. Comparedwith thosewith schizo-
phrenia, PMD patients had a higher GAF symptom score at follow-up
(coefficient 11.40, CI 4.17 to 18.62, p b 0.01); were more likely to have
an episodic course of illness (OR 7.71, CI 3.51 to 16.92, p b 0.01); had a
higher GAF disability score at follow-up (coefficient 12.78, CI 4.82 to
20.73, p b 0.01); were less likely to be employed for less than 25% of
the follow-up (OR 0.28, CI 0.12 to 0.65, p b 0.01); were more likely to
be in a relationship over the follow-up (OR 4.79, CI 2.12 to 10.85,
p b 0.01); were less likely to be admitted compulsorily (OR 0.34, CI
0.15 to 0.75, p b 0.05); and spent fewer inpatient days in hospital (coef-
ficient −243.05, CI −337.01 to −149.09, p b 0.01). The finding that
PMD patients were much less likely to go to prison over the follow-up
was no longer evident (OR 0.33, CI 0.07–1.45, p N 0.05); and there was
new evidence that PMD patients were more likely to have close confi-
dants (OR 9.21, CI 2.01 to 42.19, p b 0.01). Additionally, there was
some weak evidence (albeit not quite statistically significant at
p b 0.05) that PMD patients were more likely to attempt suicide com-
pared with schizophrenia patients (OR 2.31, CI 0.98 to 5.42, p 0.055);
and that PMD patients were more likely to self-harm (OR 2.34, CI 0.97
to 5.68, p 0.060).
3.4. Post hoc analyses
Following the finding that PMD patients had better social outcomes
compared with schizophrenia but were more likely to self-harm or at-
tempt suicide, post-hoc exploratory analyses were conducted to test
whether those who self-harmed or attempted suicide had worse social
outcomes than those who did not. There was some weak evidence
(albeit not quite statistically significant at p b 0.05) based on the base-
line diagnosis that those who attempted suicide were less likely to
have a close confidant (OR 0.19, CI 0.03–1.20, p 0.077). Based on the life-
time diagnoses, there was some weak evidence (not quite statistically
significant at p b 0.05) that PMD patients who self-harmed were more
likely to work for more than 25% of the follow-up (OR 8.57, CI 0.83–
89.04, p 0.072).
4. Discussion
Findings in this paper highlight that peoplewith PMDhave better so-
cial and service use outcomes comparedwith peoplewith schizophrenia,
but appear more likely to attempt suicide or self-harm. Outcomes for
peoplewith PMDare similar to those for peoplewith bipolar/mania. Fur-
ther, important differences between diagnostic groups were detected
when accounting for diagnostic change.
Table 2
Comparison of outcomes by baseline diagnosis.
Outcomes Comparisons
PMD SZ BP PMD vs. SZ PMD vs. BP
Clinical outcomes
Median (IQR) Median (IQR) Median (IQR) Beta coefficient (CI) Beta coefficient (CI)
Global assessment of functioning — symptoms 71.5
(58.5–80.5)
55
(42–65)
79
(65–87)
14.25
(8.13 to 20.37)⁎⁎
−4.80
(−12.27 to 2.68)
n (%) n (%) n (%) OR (CI) OR (CI)
Course of illness
Not episodic (continuous/neither) 31 (63.3) 125 (83.9) 10 (21.7) – –
Episodic 18 (36.7) 24 (16.1) 36 (78.3) 3.02 (1.46 to 6.25)⁎⁎ 0.16 (0.06 to 0.40)⁎⁎
Attempted suicide
No 35 (79.6) 119 (83.8) 36 (83.7) – –
Yes 9 (20.5) 23 (16.2) 7 (16.3) 1.33 (0.56 to 3.14) 1.32 (0.44 to 3.94)
Self-harmed
No 37 (80.4) 121 (86.4) 38 (88.4) – –
Yes 9 (19.6) 19 (13.6) 5 (11.6) 1.55 (0.65 to 3.71) 1.85 (0.57 to 6.04)
Social outcomes
Median (IQR) Median (IQR) Median (IQR) Beta coefficient (CI) Beta coefficient (CI)
Global Assessment of functioning — disability 62 (50–75) 47 (40–60) 80 (64–86) 11.22
(4.78 to 17.65)⁎⁎
−10.85
(−18.66 to−3.04)⁎⁎
n (%) n (%) n (%) OR (CI) OR (CI)
Employment status:
Employed 25–100% 20 (50.0) 34 (25.2) 17 (47.2) – –
Employed 0–25% 20 (50.0) 101 (74.8) 19 (52.8) 0.34 (0.16 to 0.70)⁎⁎ 0.89 (0.36 to 2.20)
Main relationship status:
Single/divorced/separated 19 (48.7) 110 (79.7) 23 (56.1) – –
In a relationship 20 (51.3) 28 (20.3) 18 (43.9) 4.14 (1.95 to 8.78)⁎⁎ 1.35 (0.56 to 3.24)
Close confidant:
No 8 (28.6) 37 (46.3) 6 (25.0) – –
Yes 20 (71.4) 43 (53.8) 18 (75.0) 2.15 (0.85 to 5.45) 0.83 (0.24 to 2.87)
Went to prison:
No 43 (95.6) 113 (82.5) 40 (93.0) – –
Yes 2 (4.4) 24 (17.5) 3 (7.0) 0.22 (0.05 to 0.97)⁎ 0.62 (0.10 to 3.91)
Service use outcomes
Median (IQR) Median (IQR) Median (IQR) Beta coefficient (CI) Beta coefficient (CI)
Total number of days hospitalised 63.5 (19.5–181.6) 107 (25–275) 79 (24–182) −161.98
(−272.25 to−51.70)⁎⁎
−74.44
(−235.21 to 86.34)
n (%) n (%) n (%) OR (CI) OR (CI)
Ever admitted compulsorily:
No 23 (54.8) 37 (30.8) 8 (21.1) – –
Yes 19 (45.2) 83 (69.2) 30 (79.0) 0.37 (0.18 to 0.76)⁎⁎ 0.22 (0.08 to 0.59)⁎⁎
OR= odds ratio; CI = 95% confidence interval; IQR = interquartile range; PMD = psychotic major depression; SZ = schizophrenia; BP = bipolar disorder.
⁎ p b 0.05.
⁎⁎ p b 0.01.
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(using incidence sample while accounting for diagnostic change),
these results are mostly consistent with previous research on outcomes
in PMD patients compared to schizophrenia patients even though it is
mostly based onnon-incidence samples. This previous research suggests
that compared to schizophrenia patients: PMD patients have a more
episodic course of illness (92% versus 16%;Opjordsmoen, 1989), attempt
suicide more (42% versus 27%; Radomsky et al., 1999) self-harm more
(33% versus 18%, p b 0.01; Crebbin et al., 2008), have better employment
outcomes (Bromet et al., 1996; Opjordsmoen, 1989; Jager et al., 2005;
Tsuang and Coryell, 1993; Sands and Harrow, 1999) have more stable
relationships (Jager et al., 2005), and have better social contacts
(Opjordsmoen, 1989; Tsuang and Coryell, 1993). Results from this
study are consistent with these findings. In terms of service use, the
majority of studies show that PMD patients have better inpatient out-
comes compared with schizophrenia patients (less hospitalisations,
lower scores on hospital outcomes, less continuous hospitalisations
(Jager et al., 2005; Bromet et al., 1996; Tsuang and Coryell, 1993; Sands
and Harrow, 1999; Craig et al., 1997; Craig et al., 2000). However, some
studies report worse inpatient outcomes in PMDpatients (more patients
admitted, more hospitalisations (Crebbin et al., 2008; Opjordsmoen,1989; Stephens, 1982). This study is consistent with the former as
there were less inpatient days for the PMD patients and less compulsory
admissions.
Previous research on outcomes in PMD patients compared with
patients with psychotic bipolar disorder have reported a range of non-
significant differences or conflicting findings in a range of domains
(Bromet et al., 1996; Welner et al., 1977; Aronson et al., 1987, 1988;
Winokur et al., 1992). This study is consistent with these findings as
there were minimum differences between the groups.
4.1. Limitations
As with all research, a number of limitations should be borne in mind
when considering the findings. Firstly, although loss to follow-up was
small considering the length of the study, this could have led to biased
results, perhaps by either more severe or less severe patients being lost
to follow-up. However, there were no differences in follow-up rates be-
tween the diagnostic groups. A further limitation is the simplification of
outcomes. Relationship status was categorised into ‘in a relationship’
versus ‘single/divorced/separated’. This is an over simplification of a
very complexphenomenon. It assumes that thequality of all relationships
Table 3
Comparison of outcomes by lifetime diagnosis.
Outcomes Comparisons
PMD SZ BP PMD vs. SZ PMD vs. BP
Clinical outcomes
Median (IQR) Median (IQR) Median (IQR) Beta coefficient (CI) Beta coefficient (CI)
Global assessment of functioning — symptoms 65 (57–79) 55 (41–65) 78 (65–87) 11.40
(4.17 to 18.62)⁎⁎
−8.77
(−16.86 to−0.69)⁎
n (%) n (%) n (%) OR (CI) OR (CI)
Course of illness
Not episodic (continuous/neither) 16 (44.4) 148 (86.1) 14 (25.9) – –
Episodic 20 (55.6) 24 (14.0) 40 (74.1) 7.71 (3.51 to 16.92)⁎⁎ 0.44 (0.18 to 1.07)
Attempted suicide
No 22 (68.8) 137 (83.5) 42 (82.4) – –
Yes 10 (31.3) 27 (16.5) 9 (17.7) 2.31 (0.98 to 5.42) 2.12 (0.75 to 5.99)
Self-harmed
No 26 (74.3) 142 (87.1) 42 (85.7) – –
Yes 9 (25.7) 21 (12.9) 7 (14.3)) 2.34 (0.97 to 5.68) 2.08 (0.69 to 6.25)
Social outcomes
Median (IQR) Median (IQR) Median (IQR) Beta coefficient (CI) Beta coefficient (CI)
Global Assessment of functioning — disability 65 (51–80) 48 (40–60) 81.5 (63.5–85.5) 12.78 (4.82 to 20.73)⁎⁎ −10.16 (−18.99 to−1.33)⁎
n (%) n (%) n (%) OR (CI) OR (CI)
Employment status:
Employed 25–100% 14 (52.9) 36 (23.1) 23 (54.8) – –
Employed 0–25% 13 (48.2) 120 (76.9) 19 (45.2) 0.28 (0.12 to 0.65)⁎⁎ 1.12 (0.43 to 2.96)
Main relationship status:
Single/divorced/separated 14 (46.7) 130 (80.8) 22 (47.8) – –
In a relationship 16 (53.3) 31 (19.3) 24 (52.2) 4.79 (2.12 to 10.85)⁎⁎ 1.05 (0.42 to 2.63)
Close confidant:
No 2 (10.0) 43 (50.6) 9 (30.0) – –
Yes 18 (90.0) 42 (49.4) 21 (70.0) 9.21 (2.01 to 42.19)⁎⁎ 3.86 (0.74 to 20.21)
Went to prison:
No 31 (93.9) 132 (83.5) 46 (95.8) – –
Yes 2 (6.1) 26 (16.5) 2 (4.2) 0.33 (0.07 to 1.45) 1.48 (0.20 to 11.10)
Service use outcomes
Median (IQR) Median (IQR) Median (IQR) Beta coefficient (CI) Beta coefficient (CI)
Total number of days hospitalised 22 (0–99) 128 (48–371) 73 (28–165) −243.05
(−337.01 to−149.09)⁎⁎
−54.72
(−119.59 to 10.15)
N (%) N (%) N (%) OR (CI) OR (CI)
Ever admitted compulsorily:
No 16 (51.6) 37 (26.4) 12 (25.5) – –
Yes 15 (48.4) 103 (73.6) 35 (74.5) 0.34 (0.15 to 0.75)⁎ 0.32 (0.12 to 0.84)⁎
OR= odds ratio; CI = 95% confidence interval; IQR = interquartile range; PMD = psychotic major depression; SZ = schizophrenia; BP = bipolar disorder.
⁎ p b 0.05.
⁎⁎ p b 0.01.
421M. Heslin et al. / Schizophrenia Research 176 (2016) 417–422is equivalent and that the experience of being divorced is the same as
being single or separated. Nonetheless, it provides useful information
aboutwhether a personhas apartner as a potential formof social support.
The recording and definitions of suicide attempts and self-harm are also
relatively crude; further investigation is warranted of the nature and cir-
cumstances surrounding such events. Further, the cross-sectional nature
of some of the data limits any causal links, e.g. with the finding that
PMD patients had better social outcomes compared with schizophrenia
but were more likely to self-harm or attempt suicide, both variables
were obtained using theWHO Life Chart assessed at 10 years without ac-
counting for or noting of temporality. Therefore, we cannot tell which
preceded which.
Finally, we cannot be sure whether lifetime diagnosis was influenced
by factors beyond strict operational criteria (i.e. did outcomes influence
what diagnosis was given). Lifetime diagnosis is often assumed to be
more reliable and accurate than initial diagnosis as when patients
present to services with a first episode of psychosis, the clinical picture
can be confusing: patients may be experiencing psychotic symptoms,
mood symptoms, confusion, distress, and it takes some time for the clin-
ical diagnosis to become clearer. However, information on outcomes
over time may well become (consciously or not) the basis for follow-
up diagnosis. For example, people who self-harm and/or attempt suicidemay bemore likely to get a follow-up diagnosis of PMD, and less likely to
get a follow-up diagnosis of schizophrenia. Further, as not all cases
agreed to be interviewed at follow-up, some diagnoses had to be made
on the basis of clinical notes. Thismay have introduced some bias around
what clinicians choose to record and omit. This information bias also ap-
plies to assessment of some of the outcomes (e.g. self-harm) which
would only be known about had clinicians found out, and recorded
these events in the notes. Although these are clearly problems, it is less
clear how these limitations might be overcome in future research.
4.2. Clinical implications
Based on lifetime diagnoses, PMD patients are around twice as likely
as schizophrenia patients to attempt suicide, with around a third (31%)
of patients attempting suicide at some point within the first ten years
following first episode of psychosis (although this needs to be viewed
with caution given the small sample size and consequently imprecise es-
timates of effect size). This is compared to 14.5% in a sample of depressed
patients over 5 years (Holma et al., 2010). This highlights the need for cli-
nicians to be extra vigilant of potential suicidal behaviour in PMDpatients
compared to schizophrenia patients, but also highlights the need to ex-
plore for the presence of psychotic symptoms in all depressive illness.
422 M. Heslin et al. / Schizophrenia Research 176 (2016) 417–422However, PMD patients were hospitalised less and had comparatively
good social outcomes. This contradiction is important for clinicians to
bear in mind in any risk assessment. Further, we have identified an im-
portant subgroup of patients with a different emphasis of need. People
with PMD are less likely to need help with improving social outcomes,
but may need additional support to disclose and manage self-harm
behaviour.
4.3. Future research
Although we have covered some key areas of outcome in this study
(employment, social isolation (as indicated by relationship status and
presence of a close confidant) and prison time), there are other important
domains of outcome – such as poverty and housing (Warner, 2008) –
that are beyond the scope of the data presented here. These key areas
also need to be investigated in people with PMD. Further, a better under-
standing of the incongruous findings of better social and service out-
comes but worse self-harm and suicide is needed.
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